Evaluation of the IB10 Sphingotest PCT+ in a Point-of-Care Setting
Trial Snapshot
- Phase
- Not Applicable
- Sponsor
- Enrollment
- 300
- Primary Endpoint
- To establish the precision of IB10 sphingotest PCT+ measurements in point-of-care setting with respect to frozen EDTA plasma specimens
Study Overview
Brief Summary
To establish the equivalence of IB10 sphingotest PCT+ measurements in point-of-care settings such as emergency rooms or intensive care units, with corresponding procalcitonin measurements obtained in a reference or clinical laboratory using a comparative assay, with respect to the same subset of human EDTA plasma specimens.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Diagnostic
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Subject is able and willing to provide written informed consent
- •Subject is 18 years of age or older
- •Subject is presenting with symptoms suggestive of bacterial infection
- •Subject is presenting with two or more of the following symptoms suggestive of systemic inflammatory response syndrome (SIRS):
- •Body temperature less than 36°C (96.8°F) or greater than 38°C (100.4°F);
- •Heart rate greater than 90 beats per minute;
- •Respiratory rate greater than 20 breaths per minute, or an arterial partial pressure of carbon dioxide (pCO2) less than 4.3 kPa (32 mmHg);
- •White blood cell count less than 4,000 cells/mm3 (4 x 109 cells/L) or greater than 12,000 cells/mm3 (12 x 109 cells/L);
- •A normal white blood cell count with the presence of greater
- •than 10% immature neutrophils.
Exclusion Criteria
- •Subjects less than 18 years of age;
- •Subjects who do not present with a minimum of two symptoms suggestive of SIRS, as defined above
- •Subjects unable or unwilling to provide written informed consent
Outcomes
Primary Outcomes
To establish the precision of IB10 sphingotest PCT+ measurements in point-of-care setting with respect to frozen EDTA plasma specimens
Time Frame: 1 day
Point of Care precision Testing
To establish the in vitro stability of EDTA whole blood and plasma speciments with respect to procalitonin concentrations as measured by the of IB10 sphingotest PCT+ test.
Time Frame: 1 day
in vitro stability
To establish the equivalence of IB10 sphingotest PCT+ measurements in point-of-care settings, with corresponding procalcitonin measurements obtained in a ref or clinical laboratory using a comparative assay, with respect to the same EDTA plasma specimens
Time Frame: 1 day
Method comparison
To establish the equivalence of IB10 sphingotest PCT+ measurements in EDTA whole blood and plasma specimens, as obtained in point-of-care settings as defined above
Time Frame: 1 day
Method comparison
To establish equivalence of IB10 sphingotest PCT+ measurements in fresh EDTA plasma specimens and frozen EDTA plasma specimens
Time Frame: 24 hours
in vitro stability
Secondary Outcomes
No secondary outcomes reported